About the Ypsomed Group
The Ypsomed Group is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1 600 employees.
Ypsomed Diabetes Care
With its mylife™ Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed’s subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).
Ypsomed Delivery Systems
Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world’s largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.
In the financial year 2019/20, our sales will amount to around CHF 415 million. At the EBIT level, we expect an amount between CHF 25 million and CHF 30 million for the 2019/20 financial year. For continuing operations, this corresponds to a growth of 119 % to 163 %. Based on our growth strategy, we are committed to a medium-term EBIT target of over CHF 100 million.
Key financial figures: multi-year overview
|In thousand CHF||2018/19||2017/18||2016/17||2015/16|
|Sales of goods and services||453 765||466 119||389 555||336 922|
|Gross profit||156 413||139 825||125 478||103 187|
|Operating profit||73 344||61 070||55 298||44 435|
|Net profit||60 136||52 060||46 247||35 812|
|EBITDA1||118 232||95 539||87 763||73 270|
|Cash flow from operating activities||59 859||53 269||75 064||76 687|
|Headcount||1 604||1 451||1 314||1 166|
1 Operating proﬁt before depreciation and Amortisation.